



Published in final edited form as:

J Psychopathol Clin Sci. 2024 October ; 133(7): 527–540. doi:10.1037/abn0000901.

Machine learning models for temporally precise lapse prediction in alcohol use disorder

Kendra Wyant¹, Sarah J. Sant’Ana¹, Gaylen E. Fronk¹, John J. Curtin¹

¹Department of Psychology, University of Wisconsin-Madison

Abstract

We developed three machine learning models that predict hour-by-hour probabilities of a future lapse back to alcohol use with increasing temporal precision (i.e., lapses in the next week, next day, and next hour). Model features were based on raw scores and longitudinal change in theoretically implicated risk factors collected through ecological momentary assessment (EMA). Participants ($N=151$; 51% male; mean age = 41; 87% White, 97% Non-Hispanic) in early recovery (1–8 weeks of abstinence) from alcohol use disorder provided 4x daily EMA for up to three months. We used grouped, nested cross-validation to select best models and evaluate the performance of those best models. Models yielded median areas under the receiver operating curves (auROCs) of .89, .90, and .93 in the 30 held-out test sets for week, day, and hour level models, respectively. Some feature categories consistently emerged as being globally important to lapse prediction across our week, day, and hour level models (i.e., past use, future self-efficacy). However, most of the more punctate, time-varying constructs (e.g., craving, past stressful events, arousal) appear to have greater impact within the next hour prediction model. This research represents an important step toward the development of a smart (machine learning guided) sensing system that can both identify periods of peak lapse risk and recommend specific supports to address factors contributing to this risk.

General scientific summary: This study suggests that densely sampled self-report data can be used to predict lapses back to alcohol use with varying degrees of temporal precision. Additionally, the contextual features contributing to risk of lapse may offer important insight for treatment matching through a digital therapeutic.

Keywords

ecological momentary assessment; digital therapeutics; alcohol use disorder

Introduction

Over 30 million adults in the United States (US) had an active alcohol use disorder (AUD) in 2021, and 23.3% reported engaging in past-month binge drinking (SAMHSA Center for Behavioral Health Statistics and Quality, 2021). Alcohol ranks as the third leading preventable cause of death in the US, accounting for approximately 140,000 fatalities

Correspondence concerning this article should be addressed to John J. Curtin, Department of Psychology, University of Wisconsin-Madison, 1202 W Johnson St, Madison, WI 53521, jjcurtin@wisc.edu.
KW & SJS contributed equally as co-first authors.

(Centers for Disease Control and Prevention (CDC), n.d.) and economic costs that exceed \$249 billion annually (Substance Abuse and Mental Health Services Administration (US) & Office of the Surgeon General (US), 2016).

Existing clinician-delivered treatments for AUD that were derived from Marlatt's relapse prevention model (Marlatt & Gordon, 1985) are effective when delivered (e.g., cognitive-behavioral therapy, mindfulness-based relapse prevention (Bowen et al., 2014)). Unfortunately, fewer than 1 in 20 adults with an active AUD receive any treatment (SAMHSA Center for Behavioral Health Statistics and Quality, 2021). Even more concerning, failure to access treatment is associated with demographic factors including race, ethnicity, geographic region, and socioeconomic status, which further increase mental health disparities (Office of the Surgeon General (US) et al., 2001). This treatment gap and associated disparities stem from well-known barriers to receiving clinician-delivered mental healthcare related to affordability, accessibility, availability, and acceptability (Jacobson et al., 2022).

Digital therapeutics may help to overcome these barriers associated with in-person, clinician-delivered treatments. Digital therapeutics provide evidence-based interventions and other supports via smartphones to prevent, treat, or manage a medical disorder, either independently or in conjunction with traditional treatments (Jacobson et al., 2022). They offer highly scalable, on-demand therapeutic support that is accessible whenever and wherever it is needed most. Several large, randomized controlled trials have confirmed that digital therapeutics for AUD improve clinical outcomes (Campbell et al., 2014; Gustafson et al., 2014; Jacobson et al., 2022). Additionally, US adults (including patients with AUD (Wyant et al., 2023)) display high rates of smartphone ownership (over 85% in 2021), with minimal variation across race, ethnicity, socioeconomic status, and geographic settings (Center, 2021). Therefore, digital therapeutics may not only mitigate in-person treatment barriers but also combat associated disparities (Jacobson et al., 2022).

Improving Digital Therapeutics via Personal Sensing

Despite the documented benefits of digital therapeutics, their full potential has not yet been realized. Patients often don't engage with digital therapeutics as developers intended, and long-term engagement may not be sustained or matched to patients' needs (Hatch et al., 2018; Jacobson et al., 2022). The substantial benefits of digital therapeutics come from easy, 24/7 access to their intervention and other support modules. However, the burden falls primarily on the patient to identify the most appropriate modules for them in that specific moment during their recovery.

This difficulty is magnified by the dynamic, chronic, and relapsing nature of AUD (Brandon et al., 2007). Numerous risk and protective factors interact in complex, non-linear ways to influence the probability, timing, and severity of relapse (i.e., a goal-inconsistent return to frequent, harmful alcohol use) (Witkiewitz & Marlatt, 2007). Factors such as urges, mood, lifestyle imbalances, self-efficacy, and motivation can all vary over time. Social networks may evolve to become more protective or risky, and high-risk situations can arise unexpectedly. Consequently, both relapse risk and the factors driving that risk fluctuate over time.

Successful, continuous monitoring of risk for relapse and its contributing factors would enable patients to adapt their lifestyle, behaviors, and supports to their changing needs. Successful monitoring could also direct patients to engage with the most appropriate digital therapeutic modules, addressing the unique risks present at any given moment throughout their recovery. Such continuous monitoring is now feasible via personal sensing (i.e., in-situ data collection via sensors embedded in individuals' daily lives) (Bae et al., 2018; Chih et al., 2014; Epstein et al., 2020; Moshontz et al., 2021; Soyster et al., 2022; Wyant et al., 2023).

The current project focuses explicitly on using ecological momentary assessment (EMA) for monitoring risk of return to alcohol use. EMA can be easily implemented with only a smartphone. Moreover, comparable item responses can be collected consistently across different hardware and operating systems. Thus, EMA can be incorporated essentially identically into any existing or future smartphone-based digital therapeutic. EMA, like other personal sensing methods, can support the frequent, in-situ, longitudinal measurement necessary for monitoring fluctuating relapse risk. Long-term monitoring with EMA has been well-tolerated by individuals with AUD (Wyant et al., 2023). Additionally, previous research has validated the use of EMA to measure known risk and protective factors for relapse, including craving (Dulin & Gonzalez, 2017), mood (Russell et al., 2020), stressors (Wemm et al., 2019), positive life events (Dvorak et al., 2018), and motivation/efficacy (Dvorak et al., 2014). EMA offers privileged access into these and other subjective factors that may be difficult to quantify reliably through other sensing methods.

Promising Preliminary Research

Preliminary research is now emerging that uses EMA responses as features in machine learning models to predict the probability of future alcohol use (Bae et al., 2018; Chih et al., 2014; Soyster et al., 2022; Walters et al., 2021). This research is important because it rigorously required strict temporal ordering necessary for true prediction, with features measured before alcohol use outcomes. It also used resampling methods (e.g., cross-validation) that prioritize model generalizability to increase the likelihood these models will perform well with new people.

Despite this initial promise, several important limitations exist. Some prediction models have been trained using convenience samples (e.g., college students) (Bae et al., 2018; Soyster et al., 2022). Other models have been developed to predict hazardous alcohol use in non-treatment-seeking populations (Walters et al., 2021). In both these instances, features that predict planned or otherwise intentional alcohol use among individuals not motivated to change their behavior may not generalize to people in AUD recovery. Moreover, individuals who have not yet begun to contemplate and/or commit to behavior change regarding their alcohol use are unlikely to use digital therapeutics designed for AUD recovery (Prochaska et al., 1992).

A handful of other models have been trained to predict putative precursors of substance use, such as craving (Burgess-Hull et al., 2022; Dumortier et al., 2016) and stress (Epstein et al., 2020). Although craving and stress may be associated with substance use, their relationships with relapse are complex, inconsistent, and not always very strong (Fronk et al., 2020;

Sayette, 2016). For these reasons, we believe that explicit substance use may be a better target for prediction.

With respect to explicit substance use, we also argue that models that predict lapses (i.e., single instances of goal-inconsistent substance use) rather than relapse may be preferred. Lapses are clearly defined, observable, and have temporally precise onsets and offsets. Conversely, definitions of relapse vary widely (Witkiewitz & Marlatt, 2007), and it is difficult to delineate precisely when relapse begins or ends. Lapses always precede relapse and therefore may serve as an early warning sign for intervention. Finally, maladaptive responses to a lapse (e.g., abstinence violation effects; (Marlatt & Gordon, 1985)) can undermine recovery by themselves, making lapses clinically meaningful events to detect and address.

An early alcohol lapse prediction model developed by Gustafson and colleagues (Chih et al., 2014) provided the foundation on which our current project builds. Participants completed EMAs once per week for 8 months while using a digital therapeutic after discharge from an inpatient treatment program for AUD. These EMAs were used as features in a machine learning model to predict lapses. However, the temporal precision for both the features and outcome was coarse. Model predictions were updated only once per week at most, and lapse onsets could occur anytime within the next two weeks. This coarseness restricts the model from being used to implement *just-in-time* interventions (e.g., guided mindfulness or other stress reduction techniques, urge surfing) that are well-suited to digital therapeutics.

The Current Study

The current study addresses these limitations of previously developed prediction models. We trained our models using participants in early recovery from moderate to severe AUD who reported a goal of alcohol abstinence. We developed three separate models that provide hour-by-hour probabilities of a future lapse back to alcohol use with increasing temporal precision: lapses in the next week, next day, and next hour. Model features were engineered from raw scores and longitudinal change in responses to 4X daily EMAs. These features were derived to measure theoretically-implicated risk factors and contexts that have considerable support as predictors of lapses including past use, craving, past pleasant events, past and future risky situations, past and future stressful events, emotional valence and arousal, and self-efficacy (Fronk et al., 2020; for reviews, see Marlatt & Gordon, 1985; Witkiewitz & Marlatt, 2007).

In this study, we characterize the performance of these three prediction models in held-out data (i.e., for observations from participants who were not used to train the models). We also evaluated the relative feature importance of key relapse prevention constructs in the models as part of the model validation process and to contribute to the relapse prevention literature. This research represents an important step toward the development of a “smart” (machine learning guided) sensing and prediction system that can be embedded within a digital therapeutic both to identify periods of peak lapse risk and to recommend specific supports to address factors contributing to this risk.

Method

Transparency and Openness

We adhere to research transparency principles that are crucial for robust and replicable science. We reported how we determined the sample size, all data exclusions, all manipulations, and all study measures. We provide a transparency report in the supplement. Finally, our data, analysis scripts, annotated results, questionnaires, and other study materials are publicly available (<https://osf.io/w5h9y/>).

Our study design and analyses were not pre-registered. However, we restricted many researcher degrees of freedom via cross-validation. Cross-validation inherently includes replication; models are fit on held-in training sets, decisions are made in held-out validation sets, and final performance is evaluated on held-out test sets.

Participants

We recruited 151 participants in early recovery (1–8 weeks of abstinence) from AUD in Madison, Wisconsin, US. This sample size was determined based on traditional power analysis methods for logistic regression (Hsieh, 1989) because comparable approaches for machine learning models have not yet been validated. Participants were recruited through print and targeted digital advertisements and partnerships with treatment centers. We required participants:

1. were age 18 or older,
2. could write and read in English,
3. had at least moderate AUD (≥ 4 self-reported DSM-5 symptoms),
4. were abstinent from alcohol for 1–8 weeks, and
5. were willing to use a single smartphone (personal or study provided) while on study.

We also excluded participants exhibiting severe symptoms of psychosis or paranoia.

Procedure

Participants completed five study visits over approximately three months. After an initial phone screen, participants attended an in-person screening visit to determine eligibility, complete informed consent, and collect self-report measures. Eligible, consented participants returned approximately one week later for an intake visit. Three additional follow-up visits occurred about every 30 days that participants remained on study. Participants were expected to complete four daily EMAs while on study. Other personal sensing data streams (geolocation, cellular communications, sleep quality, and audio check-ins) were collected as part of the parent grant's aims (R01 AA024391).

Measures

Ecological Momentary Assessments—Participants completed four brief (7–10 questions) EMAs daily. The first and last EMAs of the day were scheduled within one

hour of participants' typical wake and sleep times. The other two EMAs were scheduled randomly within the first and second halves of their typical day, with at least one hour between EMAs. Participants learned how to complete the EMA and the meaning of each question during their intake visit.

On all EMAs, participants reported dates/times of any unreported past alcohol use. Next, participants rated the intensity of four recent experiences:

- craving ["How intense was your greatest urge to drink?"],
- risky situations ["Did you encounter any risky situations (people, places, or things)? If yes, rate the intensity of the situation."],
- stressful events ["Has a hassle or stressful event occurred? If yes, rate the intensity of the event."],
- pleasant events [Has a pleasant or positive event occurred? If yes, rate the intensity of the event."].

For each of these experiences, participants rated the maximum intensity since their last EMA on a 12-point ordinal scale (mid- and end-point anchors of "Mild", "Moderate", and "Strong"). If they did not experience an event since their last EMA, participants selected "No" to indicate that no experience occurred for that respective question.

Next, participants rated their current affect using 11-point bipolar scales measuring valence (end-point anchors of "Unpleasant/Unhappy" to "Pleasant/Happy") and arousal (end-point anchors of "Calm/Sleepy" to "Aroused/Alert").

On the first EMA each day, participants used an 11-point bipolar scale (end-point anchors of "Very Unlikely" to "Very Likely") to rate the likelihood of:

- future risky situations ["How likely are you to encounter risky situations (people, places, or things) within the next week?"],
- future stressful events ["How likely are you to encounter a stressful event within the next week?"],
- abstinence efficacy ["How likely are you to drink any alcohol within the next week?"].

Individual Differences—We collected self-report information about demographics (age, sex, race, ethnicity, education, marital status, employment, and income) and clinical characteristics (AUD milestones, number of quit attempts, lifetime AUD treatment history, lifetime receipt of AUD medication, DSM-5 AUD symptom count, and current drug use (WHO ASSIST Working Group, 2002)). This information was collected primarily to characterize the sample and to evaluate the diversity of the training data. We also included demographic features in our models to quantify the importance of relapse prevention constructs beyond these static characteristics, given known disparities in AUD and other health outcomes (Jacobson et al., 2022)¹.

Data Analytic Strategy

Data preprocessing, modeling, and Bayesian analyses were done in R using the tidymodels ecosystem (Kuhn & Wickham, 2020). Models were trained and evaluated using high-throughput computing resources provided by the University of Wisconsin Center for High Throughput Computing (Center for High Throughput Computing, 2006).

Lapse Labels—We predicted future lapses in three prediction window widths: one week, one day, and one hour. Prediction windows were updated hourly. All classification models provide hour-by-hour predictions of future lapse probability for all three window widths.

For each participant, the first prediction window for all three widths began at midnight on their second day of participation and ended one week, one day, or one hour later. This ensured at least 24 hours of past EMAs for future lapse prediction in these first windows. Subsequent windows for each participant were created by repeatedly rolling the window start/end forward one hour until the end of their study participation (i.e., each participant's last prediction window started one week, one day, or one hour before their last recorded EMA).

We labeled each prediction window as *lapse* or *no lapse* using participants' reports from the EMA question "Have you drank any alcohol that you have not yet reported?". If participants answered yes to this question, they entered the date and hour of the start and end of the drinking episode. During monthly follow-up sessions, participants could review and correct their lapses reported by EMA and report to staff any additional lapses.

A prediction window was labeled *lapse* if the start date/hour of any drinking episode fell within that window. A window was labeled *no lapse* if no alcohol use occurred within that window \pm 24 hours. If no alcohol use occurred within the window but did occur within 24 hours of the start or end of the window, the window was excluded. We used this conservative 24-hour fence for labeling windows as *no lapse* (vs. excluded) to increase the fidelity of these labels. Given that most windows were labeled *no lapse*, and the outcome was highly unbalanced, it was not problematic to exclude some *no lapse* events to further increase confidence in those labels.

Feature Engineering—Features were calculated using only data collected before the start of each prediction window to ensure our models were making true *future predictions*. We created features for both baseline and full models. The baseline models were developed to determine how well we could predict lapses using a simple model based only on the participants' histories of previous lapses. The full models used all EMA responses combined with demographic and day/time features.

The baseline models had only one dummy-coded feature: lapse frequency (high vs. low). The median number of lapses across participants during the study period was 1. Therefore, the lapse frequency feature was coded low when the participant had a history of 1 or fewer

¹Features for income and employment were inadvertently excluded from all models.

lapses before that prediction window. This feature was coded high when the participant had more than 1 lapse before that window.

Features for the full model were derived from three sources: 1) common demographic characteristics, 2) day of the week and hour of the day at prediction window onset, and 3) previous EMA responses. We created a quantitative feature for age, and dummy-coded features for sex (male vs. female), race/ethnicity (White/Non-Hispanic vs. other), marital status (never married vs. married vs. other), and education (high school or less vs. some college vs. 4-year degree or more). We created dummy-coded features to indicate time of day (5pm - midnight vs. any other time) and day of week that the prediction window began.

We created raw EMA features for varying scoring epochs before the start of the prediction window for all EMA items excluding the alcohol use question. For the six EMA questions that appeared on all four daily EMAs, we used five scoring epochs of 12, 24, 48, 72, and 168 hours. For the three EMA questions that only appeared on the morning EMA, we used three scoring epochs of 48, 72, and 168 hours. Raw features included min, max, and median scores for each EMA question across all EMAs in each epoch for that participant. We calculated change features by subtracting the participant's mean score for each EMA question (using all EMAs collected before the start of the prediction window) from the associated raw feature. These change features allowed us to capture within-subject effects by comparing recent EMA responses relative to an individual's own baseline. For both raw and change features, the feature was set to missing (and later imputed; see below) if no responses to the specific EMA question were provided by the participant within the associated scoring epoch.

We also created raw and change features based on the most recent response for each EMA question (excluding the alcohol use question). This generated two features for each EMA question: 1) raw value of the most recent previous response, and 2) difference between that raw value and the mean response to that EMA question over all EMAs collected before that prediction window.

We also calculated raw and change rate features from previously reported lapses. We calculated lapse rate features using the same five scoring epochs described earlier. Raw lapse rate features were generated by dividing the total number of previously observed lapses within a scoring epoch by the duration of that epoch. For change rate features, we subtracted the rate of previous lapses for that participant (i.e., total number of lapses while on-study divided by total hours on-study before the prediction window) from their associated raw lapse rate. We employed a similar approach to calculate raw and change rate of missing EMAs (i.e., number of full EMA surveys that were requested but not completed in a scoring epoch / duration of epoch).

Other generic feature engineering steps included: 1) imputing missing data (median imputation for numeric features, mode imputation for nominal features); 2) dummy coding for nominal features; and 3) removing zero-variance features. Medians/modes for missing data imputation and identification of zero variance features were derived from held-in (training) data and applied to held-out (validation and test) data (see Cross-validation section

below). We recognize that median/mode imputation is a coarse method for handling missing data; however, computational costs of more sophisticated methods (e.g., KNN imputation, multiple imputation) were not practical for this study. A sample feature engineering script (i.e., tidymodels recipe) containing all feature engineering steps is available on our OSF study page.

Model Training and Evaluation

Statistical Algorithm and Hyperparameters.: We trained and evaluated six separate classification models: one baseline and one full model for each prediction window (week, day, and hour). We initially considered four well-established statistical algorithms (XGBoost, Random Forest, K-Nearest Neighbors, and Elastic Net) that vary across characteristics expected to affect model performance (e.g., flexibility, complexity, handling higher-order interactions natively) (Kuhn & Johnson, 2018). However, preliminary exploratory analyses suggested that XGBoost consistently outperformed the other three algorithms². Furthermore, the Shapley Additive Explanations (SHAP) method, which we planned to use for explanatory analyses of feature importance in our full models, is optimized for XGBoost. Consequently, we focused our primary model training and evaluation on the XGBoost algorithm only.

Candidate XGBoost model configurations differed across sensible values for the hyperparameters mtry, tree depth, and learning rate using grid search. All configurations used 500 trees with early stopping to prevent over-fitting. All other hyperparameters were set to tidymodels package defaults. Candidate model configurations also differed on outcome resampling method (i.e., up-sampling and down-sampling of the outcome using majority/no lapse to minority/lapse ratios ranging from 1:1 to 5:1). We calibrated predicted probabilities using the beta distribution to support optimal decision-making under variable outcome distributions (Kull et al., 2017).

Model training and evaluation used all participants (N = 151), regardless if they had any positive labels (i.e., lapses) because XGBoost itself does not use grouping of observations within participants. This grouping is handled instead by a participant-grouped cross-validation procedure (below).

Performance Metric.: Our primary performance metric for model selection and evaluation was area under the Receiver Operating Characteristic Curve (auROC) (Kuhn & Johnson, 2018). auROC indexes the probability that the model will predict a higher score for a randomly selected positive case (lapse) relative to a randomly selected negative case (no lapse). This metric was selected because it 1) combines sensitivity and specificity, which are both important characteristics for clinical implementation; 2) is an aggregate metric across all decision thresholds, which is important because optimal decision thresholds may differ across settings and goals; and 3) is unaffected by class imbalance, which is important for comparing models with differing prediction window widths and levels of class imbalance.

²In early exploratory analyses, we evaluated auROCs of all four algorithms using grouped k-fold cross-validation for models based on preliminary feature engineering using the EMAs. XGBoost models consistently outperformed other algorithms such that we focused all further development on XGBoost to reduce the substantial computational time associated with model training and evaluation.

Cross-validation.: We used participant-grouped, nested cross-validation for model training, selection, and evaluation with auROC. Grouped cross-validation assigns all data from a participant as either held-in or held-out to avoid bias introduced when predicting a participant's data from their own data. Nested cross-validation uses two nested loops for dividing and holding out folds: an outer loop, where held-out folds serve as *test sets* for model evaluation; and inner loops, where held-out folds serve as *validation sets* for model selection. Importantly, these sets are independent, maintaining separation between data used to train the models, select the best models, and evaluate those best models. Therefore, nested cross-validation removes optimization bias from the evaluation of model performance in the test sets and can yield lower variance performance estimates than single test set approaches (Jonathan et al., 2000).

We used 1 repeat of 10-fold cross-validation for the inner loops and 3 repeats of 10-fold cross-validation for the outer loop. Best model configurations were selected using median auROC across the 10 *validation sets*. Final performance evaluation of those best model configurations used median auROC across the 30 *test sets*. We report median auROC for our six best model configurations in the test sets. For completeness, we also report auROCs for these models from the validation sets in the Supplement. In addition, we report other key performance metrics for the best full model configurations including sensitivity, specificity, balanced accuracy, positive predictive value (PPV), and negative predictive value (NPV) from the test sets (Kuhn & Johnson, 2018).

Bayesian Estimation of auROC and Model Comparisons—We used a Bayesian hierarchical generalized linear model to estimate the posterior probability distributions and 95% Bayesian confidence intervals (CIs) for auROC for the six best models. To estimate the probability that the full model outperformed the baseline model, we regressed the auROCs (logit transformed) from the 30 test sets for each model as a function of model type (baseline vs. full). To determine the probability that full models' performances differed systematically from each other, we regressed the auROCs (logit transformed) from the 30 test sets for each full model as a function of prediction window width (week vs. day vs. hour). Following recommendations from the tidymodels team (Kuhn, 2022), we set two random intercepts: one for the repeat, and another for the fold within repeat (folds are nested within repeats for 3×10-fold cross-validation). We report the 95% (equal-tailed) Bayesian CIs from the posterior probability distributions for our models' auROCs. We also report 95% (equal-tailed) Bayesian CIs for the differences in performance associated with the Bayesian comparisons. For more detail on these analyses, see Bayesian Analyses in Supplemental Methods section of the Supplement.

Shapley Additive Explanations for Feature Importance—We computed Shapley Values (Lundberg & Lee, 2017) to provide a consistent, objective explanation of the importance of categories of features (based on EMA questions) across our three full models. Shapley values possess several useful properties including: Additivity (Shapley values for each feature can be computed independently and summed); Efficiency (the sum of Shapley values across features must add up to the difference between predicted and observed outcomes for each observation); Symmetry (Shapley values for two features should be equal

if the two features contribute equally to all possible coalitions); and Dummy (a feature that does not change the predicted value in any coalition will have a Shapley value of 0).

We calculated Shapley values from the 30 test sets using the SHAPforxgboost package that provides Shapley values in log-odds units for binary classification models. We averaged the three Shapley values for each observation for each feature across the three repeats to increase their stability. The additivity property of Shapley values allowed us to create 18 feature categories from the 286 separate features. We created separate feature categories for each of the nine EMA questions (excluding the alcohol use question), the rates of past alcohol use and missing surveys, the time of day and day of the week of the start of the prediction window, and the five demographic variables included in the models. For the EMA questions and rates of past alcohol use and missing surveys, these categories included all individual raw and change features across the three to five scoring epochs (see Feature Engineering above) and the most recent response. To calculate the local (i.e., for each observation) importance for each category of features, we added Shapley values across all features in a category, separately for each observation. To calculate global importance for each feature category, we averaged the absolute value of the Shapley values of all features in the category across all observations. These local and global importance scores based on Shapley values allow us to answer questions of relative feature importance. However, these are descriptive analyses because standard errors or other indices of uncertainty for importance scores are not available for Shapley values.

Results

Demographic and Clinical Characteristics

One hundred ninety-two participants were eligible. Of these, 191 consented to participate, and 169 subsequently enrolled in the study. Fifteen participants discontinued before the first monthly follow-up visit. We excluded data from one participant who did not maintain a goal of abstinence during their participation. We also excluded data from two participants due to evidence of careless responding and unusually low compliance. Our final sample consisted of 151 participants (see Figure S1 for more detail on enrollment and disposition).

The final sample included approximately equal numbers of men ($N=77$; 51.0%) and women ($N=74$; 49.0%) who ranged in age from 21 – 72 years old. The sample was majority White ($N=131$; 86.8%) and non-Hispanic ($N=147$; 97.4%). Participants self-reported a median of 9.0 DSM-5 symptoms of AUD (mean=8.9; $SD=1.9$; range=4.0–11.0) and a median of 4.0 previous quit attempts (mean=5.5; $SD=5.8$; range=0.0–30.0). Most participants ($N=84$; 55.6%) reported one or more lapses during participation. The median number of lapses per participant while on-study was 1.0 (mean=6.8; $SD = 12.0$; range=0.0–75.0). Table 1 provides more detail on demographic and clinical characteristics of the sample.

EMA Compliance, Features, and Prediction Window Labels

Participants on average completed 3.1 ($SD=0.6$) of the four EMAs each day (78.4% compliance overall). Participants completed at least one EMA on 95.0% of days. Across individual weeks on-study, EMA compliance percentages ranged from 75.3% – 86.8%

completion for all of the 4x daily EMAs and from 91.7% – 99.1% for at least one daily EMA completed (see Figure S2).

Using these EMA reports, we created datasets with 270,081, 274,179, and 267,287 future prediction windows for the week, day, and hour window widths, respectively. Each dataset contained 286 features and an outcome labeled as *lapse* or *no lapse*. These datasets were unbalanced with respect to the outcome such that lapses were observed in 68,467 (25.4%) week windows, 21,107 (7.7%) day windows, and 1,017 (0.4%) hour windows.

Features had missing values if the participant did not respond to the relevant EMA question during the associated scoring epoch. The median proportions of missing values across features were relatively low: 0.020 (range = 0 – 0.121), 0.022 (range = 0 – 0.125), and 0.023 (range = 0 – 0.127) for the week, day, and hour prediction windows. There were no missing values for demographic features, the hour and day of the start of the prediction window, or lapse rate and missing survey rate features (see Figure S3 for histograms of missingness).

Model Performance

auROC for Baseline Models—We selected the best *baseline model* (previous lapse frequency feature only) configurations using auROCs from the *validation sets*. We report the median and IQR auROCs from the validation sets for these best baseline model configurations in Supplemental Results. We evaluated these best baseline model configurations using *test set* performance to remove the optimization bias present in performance metrics from validation sets. The median auROC across the 30 test sets was moderate for the week (median=0.792, IQR=0.079, range=0.671–0.915), day (median=0.784, IQR=0.070, range=0.687–0.890), and hour (median=0.779, IQR=0.077, range=0.675–0.884) prediction windows.

We used the 30 test set auROCs to estimate the posterior probability distribution for the auROC of these baseline models. The median auROCs from these posterior distributions were 0.798 (week), 0.785 (day), and 0.780 (hour). These values represent our best estimates for the magnitude of the auROC parameter for each model. The 95% Bayesian CI for the auROCs for these models were relatively narrow and did not contain 0.5 (chance performance) for any window width: week [0.770–0.822], day [0.757–0.810], hour [0.752–0.806].

auROCs for Full Models—We next selected the best *full model* (which included all features) configurations using auROCs from the *validation sets*. We report the median and IQR auROCs from the validation sets for these best full model configurations in Supplemental Results. We evaluated these best full model configurations using *test set* performance. The median auROC across the 30 test sets was high for the week (median=0.891, IQR=0.043, range=0.785–0.963), day (median=0.899, IQR=0.05, range=0.788–0.969), and hour (median=0.929, IQR=0.045, range=0.847–0.972) prediction windows. Figure 1 (left panel) displays the ROC curves by prediction window derived by aggregating predicted lapse probabilities across all test sets. Figure S4 presents the individual ROC curves from each test set.

The right panel of Figure 1 displays posterior probability distributions for the auROC for the full models by prediction window. The median auROCs from these posterior distributions were 0.895 (week), 0.905 (day), and 0.930 (hour). These values represent our best estimates for the magnitude of the auROC parameter for each model. The 95% Bayesian CI for the auROCs for these models were relatively narrow and did not contain 0.5 (chance performance) for any window width: week [0.876–0.910], day [0.888–0.919], hour [0.916–0.940].

Bayesian Comparisons of Baseline vs. Full Models—We used the posterior probability distributions for the auROCs to formally compare the baseline vs. full models (matched for prediction window). The median increase in auROC for the full vs. baseline week model was 0.097 (95% CI=[0.081–0.114], yielding a probability of 1.000 that the full week model had superior performance. The median increase in auROC for the full vs. baseline day model was 0.120 (95% CI=[0.102–0.138], yielding a probability of 1.000 that the full day model had superior performance. The median increase in auROC for the full vs. baseline hour model was 0.149 (95% CI=[0.131–0.170], yielding a probability of 1.000 that the full hour model had superior performance. Figure S5 presents histograms of the posterior probability distributions for these model contrasts on auROC.

Bayesian Comparisons of Full Models by Prediction Window—We also used the posterior probability distributions for the auROCs for the three full models to formally compare the differences in performance by prediction window width. The median increase in auROC for the hour vs. the day model was 0.025 (95% CI=[0.017–0.034], yielding a probability of 1.000 that the hour (vs. day) model had superior performance. The median increase in auROC for the hour vs. the week model was 0.035 (95% CI=[0.026–0.045], yielding a probability of 1.000 that the hour model (vs. week) had superior performance. The median increase in auROC for the day vs. the week model was 0.010 (95% CI=[0.001–0.020], yielding a probability of 0.982 that the day (vs. week) model had superior performance. Figure S6 presents histograms of the posterior probability distributions for these prediction window width contrasts on auROC.

Other Performance Metrics for the Full Models—Figure S7 displays histograms for the predicted probabilities of lapse for all observations in the 30 *test sets* separately by prediction window and true outcome for the full models. We evaluated the sensitivity, specificity, balanced accuracy, PPV, and NPV when these predicted lapse probabilities were used for binary classification (*lapse* vs. *no lapse*) with decision thresholds identified by Youden's Index. All three full models had high sensitivity, specificity, balanced accuracy, and NPV (Table 2). PPV, however, notably declined as the prediction window width decreased.

PPV can be increased by increasing the decision threshold; however, increasing the decision threshold will also lower the model's sensitivity. To evaluate the trade-off between PPV (i.e., precision) and sensitivity (i.e., recall) across decision thresholds, we created Precision-Recall curves by concatenating predicted lapse probabilities across the 30 test sets (Figure 2). For example, the dotted lines in Figure 2 depict the sensitivities (0.718, 0.473, and 0.327

for week, day, and hour models, respectively) associated with decision thresholds that yield 0.700 PPV for each model.

Feature Importance for Full Models

Global importance (mean |Shapley value|) for feature categories for each full model appears in Panel A of Figure 3. Past use was the most important feature category for lapse prediction across prediction window widths. Future abstinence efficacy was also globally important across window widths. Time-varying constructs (craving, time of day) appear to have more impact in lapse prediction for the hour model compared to the day and week models.

Sina plots of local Shapley values (i.e., the influence of feature categories on individual observations) for each model show that some feature categories (e.g., past pleasant events, future stressful events) impact lapse probability for specific individuals at specific times even if they are not globally important across all observations (Figure 3, Panels B-D).

Discussion

Model Performance

All baseline models, which used only past frequency of lapses to predict future lapses, performed moderately well with auROCs in the upper .70s. These results confirm what we would expect: past behavior is a relatively good predictor of future behavior. However, there was still substantial room for increased predictive performance. Furthermore, these baseline models do not identify specific risk factors contributing to lapse predictions at any moment in time for each participant.

All three full models performed exceptionally well, yielding auROCs of 0.89, 0.90, and 0.93 for week, day, and hour level models, respectively. auROCs above .9 are generally described as having “excellent” performance; the model will correctly assign a higher probability to a positive case (e.g., lapse) than a negative case 90% of the time (Mandrekar, 2010). Bayesian comparisons indicated that these full models performed better than the baseline models for the same prediction window. This confirms that EMA can predict future alcohol lapses in the next week, next day, and next hour with high sensitivity and specificity for new individuals. And, as we describe later, using features that map onto important relapse prevention risk constructs may illuminate momentary contributors to predicted lapses.

This study addressed several important limitations of previous research to advance toward robust sensing and prediction models that can be embedded within digital therapeutics. First, our models were trained on a relatively large, treatment-seeking sample of adults in early recovery from AUD that closely matches the individuals most likely to benefit from such models within a digital therapeutic. Second, we explicitly predicted episodes of goal-inconsistent alcohol use (i.e., lapses) because features that predict goal-inconsistent use likely differ from those that predict other types of alcohol use. Third, we measured EMA features and alcohol use with sufficient frequency and granularity to train well-performing models with high temporal resolution - specifically, hour-by-hour predicted probabilities for lapses in the next week, day, and hour. Fourth, we collected features and outcomes over three months during a high risk period (initial remission (Hagman et al., 2022) from AUD).

Fifth, we used cutting-edge resampling methods (grouped, nested, k-fold cross-validation) to provide valid estimates of how our models would perform with new individuals. Finally, we used interpretable machine learning methods (SHAP (Lundberg & Lee, 2017; Molnar, 2022)) to better understand how our models made predictions globally and locally for specific participants at discrete moments in time.

Understanding & Contextualizing Model Performance

We used SHAP to describe the relative importance of key relapse prevention model constructs (represented by categories of features) to predicted lapses in our three full models. Some constructs consistently emerged as globally important across week, day, and hour level models. Unsurprisingly, the largest contribution to lapse prediction was past use. This is consistent with decades of research on relapse precipitants and our understanding of human behavior more generally (i.e., past behavior predicts future behavior) (Marlatt & Gordon, 1985). Decreases in abstinence self-efficacy were also strongly associated with increased probability of future lapses across windows.

The relative importance of some constructs descriptively differed by window width. Punctate, time-varying constructs (e.g., craving, arousal, recent risky situation) had greater impact on predicted lapse probabilities in the hour model compared to day or week models. The time of day feature was relatively important (top four) in the hour model, such that lapses were more likely for hour-level prediction windows that began in the evenings. The day of week feature made a small contribution to the hour and day models given that lapses were more likely on weekends. The time and day features were not useful in the week model because its associated prediction window (a full week) spanned all days and times, making the time and day that the window began irrelevant. The increased global importance for all these punctate features/constructs to immediate lapse risk likely contributed to the hour model outperforming the day and week models. These important global differences in next hour lapse risk also highlight the need for just-in-time interventions that can address these imminent but short-lived risks.

The individual, local Shapley values also shed light on the multidimensional and heterogeneous nature of lapse risk in our sample. Sina plots of local Shapley values (Figure 3) display meaningful ranges of scores for most feature categories. This means that even feature categories with lower global importance (e.g., past pleasant events, future stressful events) still consequentially impacted predictions for some individuals at specific times. This variability in locally important features highlights the potential benefits of recommending optimal interventions and other supports that are personalized for that person at that moment in time.

Our demographic features did not display high global or local importance. Despite the diversity in sex, age, education, and marital status in our sample, these features did not meaningfully contribute to lapse prediction. Although this does not preclude these features' predictive utility, it does suggest that other EMA feature categories may be more relevant for lapse prediction than these characteristics. Race/ethnicity also did not emerge as globally or locally important features. However, the limited representation of participants of color in

our sample warrants caution in drawing conclusions about the predictive utility of race and ethnicity at this time.

Considerations for Clinical Implementation

Smart Digital Therapeutics—We believe these full models may be most effective when embedded in a “smart” digital therapeutic that guides patients toward optimal, adaptive engagement to address their ongoing and momentary risks. These models can provide the patient’s predicted future lapse probability and the features that meaningfully contribute to that probability. We consciously selected EMA items that map onto well-known risk factors from the relapse prevention literature. Consequently, these outputs can be used to recommend specific intervention and support modules that are risk-relevant for each patient - much like a clinician would do if they were available in-the-moment. For example, during sensed periods of high stress, stress reduction techniques (e.g., guided mindfulness) could be recommended. If increased time with risky people or locations is driving lapse risk, the digital therapeutic can support patients to attend support meetings, or encourage participation in the in-app discussion board.

Module recommendations can also be tuned more precisely using the patient’s current lapse probability. If increased craving yields a high predicted lapse probability, stimulus control modules would be recommended (e.g., remove drinking cues, leave unsafe environment). Conversely, if craving is detected but lapse probability is lower, urge management modules that permit coping with the craving in-place could be recommended (e.g., urge surfing, distracting activities/games).

Of course, we must first determine how best to provide module recommendations such that patients trust and follow the recommendation. Increasing the interpretability and transparency of otherwise “black box” machine learning prediction models can improve perceptions, but providing complex or unnecessary information may instead undermine trust (Molnar, 2022). Additional research using appropriate research designs is needed to optimize recommendation messaging to increase adherence and clinical outcomes (Collins, 2018).

A smart digital therapeutic can potentially improve clinical outcomes in multiple ways. First, feedback from the prediction model could improve patient insight and self-monitoring by connecting their daily experiences to changing risk. Second, it can remove patient uncertainty by guiding selection from the substantial content available. Third, a smart digital therapeutic could encourage risk-relevant engagement. Rather than trying to increase overall time using the digital therapeutic, patients could be guided to use the supports that specifically target their personal risk factors at that moment in time. Thus, smart digital therapeutics are well-positioned to pursue the precision mental health goal to “provide the right treatment to the right patient at the right time, every time” (Kaiser, 2015).

Categorical Lapse Predictions—Our models natively provide quantitative predictions of lapse probabilities. These lapse probabilities can also be used to make categorical predictions (lapse vs. no-lapse) by applying a decision threshold to the quantitative predicted lapse probabilities (i.e., predict lapse when the probability exceeds the decision threshold).

We observed high sensitivity and specificity for these categorical predictions at a decision threshold selected to balance these two performance metrics. However, the PPV (proportion of predicted lapses that were true lapses) of these categorical predictions in our full models was moderate to very low at this threshold (ranging from .630 down to .025 across window widths). For this reason, categorical predictions should be provided to patients with extreme caution, if at all. Instead, we favor the quantitative lapse probabilities as risk indicators to guide intervention and support recommendations.

If categorical predictions are necessary, PPV can be improved by raising the decision threshold, but this comes at the cost of reduced sensitivity. We explored this trade-off in the precision-recall curves displayed in Figure 2. From these curves, it is clear decision thresholds that yield higher PPV (e.g., .700) exist for all three full models, but the associated sensitivity will be lower (e.g., 0.718, 0.473, and 0.327 for the week, day, and hour models, respectively, at this threshold). Clinical implementation of categorical predictions will require selecting an optimal decision threshold after weighing the cost of missing true lapses (low sensitivity) vs. predicting lapses that subsequently do not occur (low PPV). Different thresholds could be used depending on the purpose, context, available resources, or even patient preference.

Additional Limitations and Future Directions

Successful clinical implementation of our models will require several important steps to address limitations in our work to-date. First, we need to enrich the training data to include diversity across race, ethnicity, and geographic region. Our current prediction models may not work well for people of color or people from rural communities. Prediction models must use diverse training samples to avoid exacerbating rather than mitigating existing disparities. We must also collect data from individuals in later stages of recovery beyond initial remission; features that predict lapses may differ in these later periods. We are intentionally addressing these issues in a current NIH protocol that recruits nationally for demographic and geographic diversity and follows participants for up to 1.5 years into their recovery (Moshontz et al., 2021).

The chronic nature of AUD may require sustained use of a sensing and prediction system. Consequently, the burden of using such systems must be considered. Participants with AUD find three months of 4x daily EMA to be generally acceptable and report that they could hypothetically sustain this for at least a year if there were clinical benefits to them (Wyant et al., 2023). They also report that 1x daily EMA may be more feasible still (Wyant et al., 2023). We plan to develop future prediction models that use only the single morning EMA to contrast the assessment burden vs. model performance trade-off between our current models and putatively lower burden models. We also plan to train models that use features based on passively sensed geolocation and cellular communications data-streams (i.e., meta-data from calls and text messages; text message content) that were also collected from our participants. These passively sensed signals may be sufficient as inputs to an exceptionally low burden prediction model. Alternatively, they can be added to models that also include EMA to increase model performance further and/or to reduce the frequency or length of the EMA surveys while maintaining comparable performance.

Our current models predict probability of imminent lapses. The hour and day full models are well-positioned to identify and recommend just-in-time interventions to address these immediate risks. However, the week model may not have sufficient temporal specificity to recommend immediate patient action. Instead, its clinical utility may improve if we shift this coarser window width into the future. For example, we could train a model to predict the probability of lapse at any point during a week window that begins two weeks in the future. This “time-lagged” model could provide patients with increased lead time to implement supports that might not be immediately available to them (e.g., schedule therapy appointment, request support from an AA sponsor).

Finally, XGBoost does not take advantage of grouping observations within participants or systematic variation unique to individual participants³. Independence of observations is not necessary for statistically valid prediction. When observations are grouped/repeated within participants, linear mixed effects models or other statistical models that can estimate both population-level (fixed) effects and participant-level (random) effects may predict better for the participants on which they were trained than would XGBoost. However, we are not interested in making predictions for participants in our training set. We want to know how well our models will work with new individuals like those that will use smart digital therapeutics in the future.

In some domains, there has been increasing interest in idiographic approaches where models are trained and then implemented for the same individual (Fisher et al., 2019; Wright & Zimmermann, 2019). Such approaches may also yield superior predictive performance but are not possible to implement for outcomes like alcohol use lapse. A person-specific lapse prediction model requires a sufficient number of positive labels (i.e., lapses) for that individual. It may be too late to prevent relapse if we must wait until an individual has lapsed multiple (perhaps many) times to offer help. We believe the most promising approaches may involve first developing population-based models and updating these models with person-specific information as the patient uses the system (Zhou et al., 2018). We are pursuing these cutting-edge models as a near-term future direction.

In this study, we have demonstrated that sensing and prediction systems can now be developed to predict future lapses with high temporal resolution. Important steps still remain before these systems can be embedded within smart digital therapeutics and delivered to patients. However, the necessary steps are clear and, when completed, these smart digital therapeutics hold promise to advance us toward precision mental health solutions that may reduce both barriers and disparities in AUD treatment.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

³Although XGBoost ignores participant-level information, we do leverage this information to some degree by including change features that anchor participants’ EMA responses to their own previous responses.

Acknowledgments

All data and materials have been made publicly available and can be accessed at <https://osf.io/w5h9y/>. All procedures were approved by the University of Wisconsin-Madison Institutional Review Board (Study # 2015-0780). This research was supported by grants from the NIAAA (R01 AA024391; JJC) and the NIDA (R01 DA047315; JJC). The authors wish to thank Susan E. Wanta for her role as the project administrator and for her help with data curation and Xiaojin (Jerry) Zhu for his contributions to project conceptualization and analyses. The authors also wish to thank Candace Lighthouse, Jill Nagler, Kerry Keiser, and Megan Schultz for their contributions to data collection and Chris Gioia for the clinical supervision he provided to graduate students.

References

- Bae S, Chung T, Ferreira D, Dey AK, & Suffoletto B (2018). Mobile phone sensors and supervised machine learning to identify alcohol use events in young adults: Implications for just-in-time adaptive interventions. *Addictive Behaviors*, 83, 42–47. 10.1016/j.addbeh.2017.11.039 [PubMed: 29217132]
- Bowen S, Witkiewitz K, Clifasefi SL, Grow J, Chawla N, Hsu SH, Carroll HA, Harrop E, Collins SE, Lustyk MK, & Larimer ME (2014). Relative Efficacy of Mindfulness-Based Relapse Prevention, Standard Relapse Prevention, and Treatment as Usual for Substance Use Disorders. *JAMA Psychiatry*, 71 (5), 547–556. 10.1001/jamapsychiatry.2013.4546 [PubMed: 24647726]
- Brandon TH, Vidrine JI, & Litvin EB (2007). Relapse and relapse prevention. *Annual Review of Clinical Psychology*, 3 (1), 257–284. 10.1146/annurev.clinpsy.3.022806.091455
- Burgess-Hull AJ, Panlilio LV, Preston KL, & Epstein DH (2022). Trajectories of craving during medication-assisted treatment for opioid-use disorder: Subtyping for early identification of higher risk. *Drug and Alcohol Dependence*, 233, 109362. 10.1016/j.drugalcdep.2022.109362 [PubMed: 35217274]
- Campbell ANC, Nunes EV, Matthews AG, Stitzer M, Miele GM, Polsky D, Turrigiano E, Walters S, McClure EA, Kyle TL, Wahle A, Van Veldhuisen P, Goldman B, Babcock D, Stabile PQ, Winhusen T, & Ghitza UE (2014). Internet-delivered treatment for substance abuse: A multisite randomized controlled trial. *The American Journal of Psychiatry*, 171 (6), 683–690. 10.1176/appi.ajp.2014.13081055 [PubMed: 24700332]
- Center for High Throughput Computing. (2006). Center for high throughput computing. Center for High Throughput Computing. 10.21231/GNT1-HW21
- Center, P. R. (2021). Mobile Fact Sheet. Pew Research Center.
- Centers for Disease Control and Prevention (CDC). (n.d.). Annual Average for United States 2011–2015 Alcohol-Attributable Deaths Due to Excessive Alcohol Use, All Ages. In 2022 Alcohol Related Disease Impact (ARDI) Application Website. https://nccd.cdc.gov/DPH_ARDI/Default/Default.aspx.
- Chih M-Y, Patton T, McTavish FM, Isham AJ, Judkins-Fisher CL, Atwood AK, & Gustafson DH (2014). Predictive modeling of addiction lapses in a mobile health application. *Journal of Substance Abuse Treatment*, 46 (1), 29–35. 10.1016/j.jsat.2013.08.004 [PubMed: 24035143]
- Collins LM (2018). *Optimization of Behavioral, Biobehavioral, and Biomedical Interventions: The Multiphase Optimization Strategy (MOST)*. Springer International Publishing. 10.1007/978-3-319-72206-1
- Dulin PL, & Gonzalez VM (2017). Smartphone-based, momentary intervention for alcohol cravings amongst individuals with an alcohol use disorder. *Psychology of Addictive Behaviors: Journal of the Society of Psychologists in Addictive Behaviors*, 31 (5), 601–607. 10.1037/adb0000292 [PubMed: 28703611]
- Dumortier A, Beckjord E, Shiffman S, & Sejdi E (2016). Classifying smoking urges via machine learning. *Computer Methods and Programs in Biomedicine*, 137, 203–213. 10.1016/j.cmpb.2016.09.016 [PubMed: 28110725]
- Dvorak RD, Pearson MR, & Day AM (2014). Ecological Momentary Assessment of Acute Alcohol Use Disorder Symptoms: Associations With Mood, Motives, and Use on Planned Drinking Days. *Experimental and Clinical Psychopharmacology*, 22 (4), 285–297. 10.1037/a0037157 [PubMed: 24932896]

- Dvorak RD, Stevenson BL, Kilwein TM, Sargent EM, Dunn ME, Leary AV, & Kramer MP (2018). Tension reduction and affect regulation: An examination of mood indices on drinking and non-drinking days among university student drinkers. *Experimental and Clinical Psychopharmacology*, 26 (4), 377–390. 10.1037/pha0000210 [PubMed: 29985019]
- Epstein DH, Tyburski M, Kowalczyk WJ, Burgess-Hull AJ, Phillips KA, Curtis BL, & Preston KL (2020). Prediction of stress and drug craving ninety minutes in the future with passively collected GPS data. *Npj Digital Medicine*, 3 (1), 26. <https://doi.org/ghqvcw> [PubMed: 32195362]
- Fisher AJ, Bosley HG, Fernandez KC, Reeves JW, Soyster PD, Diamond AE, & Barkin J (2019). Open trial of a personalized modular treatment for mood and anxiety. *Behaviour Research and Therapy*, 116, 69–79. 10.1016/j.brat.2019.01.010 [PubMed: 30831478]
- Fronk GE, Sant'Ana SJ, Kaye JT, & Curtin JJ (2020). Stress Allostasis in Substance Use Disorders: Promise, Progress, and Emerging Priorities in Clinical Research. *Annual Review of Clinical Psychology*, 16 (1), 401–430. 10.1146/annurev-clinpsy-102419-125016
- Gustafson DH, McTavish FM, Chih M-Y, Atwood AK, Johnson RA, Boyle MG, Levy MS, Driscoll H, Chisholm SM, Dillenburg L, Isham A, & Shah D (2014). A smartphone application to support recovery from alcoholism: A randomized clinical trial. *JAMA Psychiatry*, 71 (5), 566–572. 10.1001/jamapsychiatry.2013.4642 [PubMed: 24671165]
- Hagman BT, Falk D, Litten R, & Koob GF (2022). Defining Recovery From Alcohol Use Disorder: Development of an NIAAA Research Definition. *The American Journal of Psychiatry*, 179 (11), 807–813. 10.1176/appi.ajp.21090963 [PubMed: 35410494]
- Hatch A, Hoffman JE, Ross R, & Docherty JP (2018). Expert Consensus Survey on Digital Health Tools for Patients With Serious Mental Illness: Optimizing for User Characteristics and User Support. *JMIR Mental Health*, 5 (2), e46. 10.2196/mental.9777 [PubMed: 29895514]
- Hsieh F (1989). Sample size tables for logistic regression. *Statistics in Medicine*, 8, 795–802. [PubMed: 2772439]
- Jacobson NC, Kowatsch T, & Marsch LA (Eds.). (2022). *Digital Therapeutics for Mental Health and Addiction: The State of the Science and Vision for the Future* (1st edition). Academic Press.
- Jonathan P, Krzanowski WJ, & McCarthy WV (2000). On the use of cross-validation to assess performance in multivariate prediction. *Statistics and Computing*, 10 (3), 209–229. 10.1023/A:1008987426876
- Kaiser J (2015). Obama gives East Room rollout to Precision Medicine Initiative. In *Science*. <https://www.science.org/content/article/obama-gives-east-room-rollout-precision-medicine-initiative>.
- Kuhn M (2022). *Tidyposterior: Bayesian Analysis to Compare Models using Resampling Statistics*.
- Kuhn M, & Johnson K (2018). *Applied Predictive Modeling* (1st ed. 2013, Corr. 2nd printing 2018 edition). Springer. 10.1007/978-1-4614-6849-3
- Kuhn M, & Wickham H (2020). *Tidymodels: A collection of packages for modeling and machine learning using tidyverse principles*.
- Kull M, Filho TMS, & Flach P (2017). Beyond sigmoids: How to obtain well-calibrated probabilities from binary classifiers with beta calibration. *Electronic Journal of Statistics*, 11 (2), 5052–5080. 10.1214/17-EJS1338SI
- Lundberg SM, & Lee S-I (2017). A unified approach to interpreting model predictions. *Proceedings of the 31st International Conference on Neural Information Processing Systems*, 4768–4777.
- Mandrekar JN (2010). Receiver operating characteristic curve in diagnostic test assessment. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*, 5 (9), 1315–1316. 10.1097/JTO.0b013e3181ec173d [PubMed: 20736804]
- Marlatt GA, & Gordon JR (Eds.). (1985). *Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors* (First edition). The Guilford Press.
- Molnar C (2022). *Interpretable Machine Learning: A Guide For Making Black Box Models Explainable*. Independently published.
- Moshontz H, Colmenares AJ, Fronk GE, Sant'Ana SJ, Wyant K, Wanta SE, Maus A, Jr DHG, Shah D, & Curtin JJ (2021). Prospective Prediction of Lapses in Opioid Use Disorder: Protocol for a Personal Sensing Study. *JMIR Research Protocols*, 10 (12), e29563. 10.2196/29563 [PubMed: 34559061]

- Office of the Surgeon General (US), Center for Mental Health, S. (US)., & (US), H. (2001). Mental Health: Culture, Race, and Ethnicity. Substance Abuse and Mental Health Services Administration (US).
- Prochaska JO, DiClemente CC, & Norcross JC (1992). In search of how people change: Applications to addictive behaviors. *American Psychologist*, 47 (9), 1102–1114. 10.1037/0003-066X.47.9.1102 [PubMed: 1329589]
- Russell MA, Linden-Carmichael AN, Lanza ST, Fair EV, Sher KJ, & Piasecki TM (2020). Affect Relative to Day-Level Drinking Initiation: Analyzing Ecological Momentary Assessment Data with Multilevel Spline Modeling. *Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors*, 34 (3), 434–446. 10.1037/adb0000550 [PubMed: 31971425]
- SAMHSA Center for Behavioral Health Statistics and Quality. (2021). 2021 NSDUH Detailed Tables | CBHSQ Data. In Substance Abuse and Mental Health Services Administration. <https://www.samhsa.gov/data/report/2021-nsduh-detailed-tables>.
- Sayette MA (2016). The Role of Craving in Substance Use Disorders: Theoretical and Methodological Issues. *Annual Review of Clinical Psychology*, 12, 407–433. 10.1146/annurev-clinpsy-021815-093351
- Soyster PD, Ashlock L, & Fisher AJ (2022). Pooled and person-specific machine learning models for predicting future alcohol consumption, craving, and wanting to drink: A demonstration of parallel utility. *Psychology of Addictive Behaviors: Journal of the Society of Psychologists in Addictive Behaviors*, 36 (3), 296–306. 10.1037/adb0000666 [PubMed: 35041441]
- Substance Abuse and Mental Health Services Administration (US), & Office of the Surgeon General (US). (2016). Facing Addiction in America. US Department of Health and Human Services.
- Walters ST, Businelle MS, Suchting R, Li X, Hébert ET, & Mun E-Y (2021). Using machine learning to identify predictors of imminent drinking and create tailored messages for at-risk drinkers experiencing homelessness. *Journal of Substance Abuse Treatment*, 127, 108417. 10.1016/j.jsat.2021.108417 [PubMed: 34134874]
- Wemm SE, Larkin C, Hermes G, Tennen H, & Sinha R (2019). A day-by-day prospective analysis of stress, craving and risk of next day alcohol intake during alcohol use disorder treatment. *Drug and Alcohol Dependence*, 204, 107569. 10.1016/j.drugalcdep.2019.107569 [PubMed: 31574406]
- WHO ASSIST Working Group. (2002). The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Development, reliability and feasibility. *Addiction (Abingdon, England)*, 97 (9), 1183–1194. [PubMed: 12199834]
- Witkiewitz K, & Marlatt GA (2007). Modeling the complexity of post-treatment drinking: It's a rocky road to relapse. *Clinical Psychology Review*, 27 (6), 724–738. 10.1016/j.cpr.2007.01.002 [PubMed: 17355897]
- Wright AGC, & Zimmermann J (2019). Applied Ambulatory Assessment: Integrating Idiographic and Nomothetic Principles of Measurement. *Psychological Assessment*, 31 (12), 1467–1480. 10.1037/pas0000685 [PubMed: 30896209]
- Wyant K, Moshontz H, Ward SB, Fronk GE, & Curtin JJ (2023). Acceptability of Personal Sensing Among People With Alcohol Use Disorder: Observational Study. *JMIR mHealth and uHealth*, 11 (1), e41833. 10.2196/41833 [PubMed: 37639300]
- Zhou M, Fukuoka Y, Mintz Y, Goldberg K, Kaminsky P, Flowers E, & Aswani A (2018). Evaluating Machine Learning–Based Automated Personalized Daily Step Goals Delivered Through a Mobile Phone App: Randomized Controlled Trial. *JMIR mHealth and uHealth*, 6 (1), e9117. 10.2196/mhealth.9117




Figure 1. ROC curves and posterior probabilities for auROCs by prediction window. The left panel depicts the aggregate receiver operating characteristic (ROC) curve for each model, derived by concatenating predicted lapse probabilities across all test sets. The dotted line represents the expected ROC curve for a random classifier. The histograms on the right depict the posterior probability distribution for the areas under the receiver operating characteristic curves (auROCs) for each model. The vertical lines represent the median posterior probability and the horizontal line represents the boundaries 95% CI.




Figure 2. Precision-recall Curves by Prediction Window for the Full Models. The plot depicts the aggregate precision-recall curves for each full model, derived by concatenating predicted lapse probabilities across all test sets. The dotted lines depict the sensitivities (0.718, 0.473, and 0.327 for week, day, and hour models, respectively) associated with decision thresholds that yield 0.700 positive predictive value for each of those models.




Figure 3. Feature importance (Shapley values) for Full Models by Prediction Window. Panel A displays the global importance (mean |Shapley value|) for feature categories for each full model. Raw EMA features are grouped into categories by the original question from the EMA. Features based on the rates of previous lapses and previous missing surveys, as well as demographics, and the time of day and day of the week for the start of the prediction window are also included. Feature categories are ordered by their aggregate global importance (i.e., total bar length) across the three models. The importance of each feature category for specific models is displayed separately by color. Panels B-D display local Shapley values that quantify the influence of feature categories on individual observations (i.e., a single prediction window for a specific participant) for each model.

Table 1

Demographics and clinical characteristics

	N	%	M	SD	Range
Age			41	11.9	21–72
Sex					
Female	74	49.0			
Male	77	51.0			
Race					
American Indian/Alaska Native	3	2.0			
Asian	2	1.3			
Black/African American	8	5.3			
White/Caucasian	131	86.8			
Other/Multiracial	7	4.6			
Hispanic, Latino, or Spanish Origin					
Yes	4	2.6			
No	147	97.4			
Education					
Less than high school or GED degree	1	0.7			
High school or GED	14	9.3			
Some college	41	27.2			
2-Year degree	14	9.3			
College degree	58	38.4			
Advanced degree	23	15.2			
Employment					
Employed full-time	72	47.7			
Employed part-time	26	17.2			
Full-time student	7	4.6			
Homemaker	1	0.7			
Disabled	7	4.6			
Retired	8	5.3			
Unemployed	18	11.9			
Temporarily laid off, sick leave, or maternity leave	3	2.0			
Other, not otherwise specified	9	6.0			
Personal Income			\$34,298	\$31,807	\$0–200,000
Marital Status					
Never married	67	44.4			
Married	32	21.2			
Divorced	45	29.8			
Separated	5	3.3			
Widowed	2	1.3			
Alcohol Use Disorder Milestones					
Age of first drink			14.6	2.9	6–24

	N	%	M	SD	Range
Age of regular drinking			19.5	6.6	11–56
Age at which drinking became problematic			27.8	9.6	15–60
Age of first quit attempt			31.5	10.4	15–65
Number of Quit Attempts*			5.5	5.8	0–30
Lifetime History of Treatment (Can choose more than 1)					
Long-term residential (6+ months)	8	5.3			
Short-term residential (< 6 months)	49	32.5			
Outpatient	74	49.0			
Individual counseling	97	64.2			
Group counseling	62	41.1			
Alcoholics Anonymous/Narcotics Anonymous	93	61.6			
Received Medication for Alcohol Use Disorder					
Yes	59	39.1			
No	92	60.9			
DSM-5 Alcohol Use Disorder Symptom Count			8.9	1.9	4–11
Current (Past 3 Month) Drug Use					
Tobacco products (cigarettes, chewing tobacco, cigars, etc.)	84	55.6			
Cannabis (marijuana, pot, grass, hash, etc.)	66	43.7			
Cocaine (coke, crack, etc.)	18	11.9			
Amphetamine type stimulants (speed, diet pills, ecstasy, etc.)	15	9.9			
Inhalants (nitrous, glue, petrol, paint thinner, etc.)	3	2.0			
Sedatives or sleeping pills (Valium, Serepax, Rohypnol, etc.)	22	14.6			
Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.)	14	9.3			
Opioids (heroin, morphine, methadone, codeine, etc.)	16	10.6			
Reported 1 or More Lapse During Study Period					
Yes	84	55.6			
No	67	44.4			
Number of reported lapses			6.8	12	0–75

Note:

N = 151

Two participants reported 100 or more quit attempts. We removed these outliers prior to calculating the mean (M), standard deviation (SD), and range.

Table 2

Performance Metrics for Full models by Prediction Window

Metric	Week	Day	Hour
auROC	0.891	0.899	0.929
sensitivity	0.823	0.828	0.864
specificity	0.819	0.845	0.881
balanced accuracy	0.828	0.835	0.854
positive predictive value	0.630	0.300	0.025
negative predictive value	0.944	0.988	0.999

Note: Areas under the receiver operating characteristic curves (auROCs) summarize the model's sensitivity and specificity over all possible decision thresholds. Sensitivity, specificity, balanced accuracy, positive predictive value, and negative predictive value are performance metrics calculated at a single decision threshold for each model determined with Youdens index. All metrics represent median values across 30 held-out test sets.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript